Met Life Investment Management, LLC Nuvalent, Inc. Transaction History

Met Life Investment Management, LLC

$16.5 Billion
Q2 2025

A detailed history of Met Life Investment Management, LLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 25,706 shares of NUVL stock, worth $1.97 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

25,706

Previous 20,763 23.81%

Holding current value

$1.97 Million

Previous $1.47 Million 33.22%

% of portfolio

0.01%

Previous 0.01%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$59.32 - $79.68 $293,218 - $393,858	4,943 Added 23.81%	25,706 $1.96 Million
Q1 2025 May 14, 2025	SELL	$67.38 - $88.96 $22,235 - $29,356	-330 Reduced 1.56%	20,763 $1.47 Million
Q4 2024 Feb 13, 2025	BUY	$77.87 - $104.93 $105,591 - $142,285	1,356 Added 6.87%	21,093 $1.65 Million
Q3 2024 Nov 13, 2024	BUY	$67.44 - $112.17 $83,018 - $138,081	1,231 Added 6.65%	19,737 $2.02 Million
Q2 2024 Aug 13, 2024	BUY	$62.76 - $81.61 $281,666 - $366,265	4,488 Added 32.02%	18,506 $1.4 Million
Q1 2024 May 14, 2024	BUY	$72.35 - $88.99 $1.01 Million - $1.25 Million	14,018 New	14,018 $1.05 Million
Q4 2023 Feb 14, 2024	BUY	$42.42 - $80.28 $52,431 - $99,226	1,236 Added 9.67%	14,018 $1.03 Million
Q3 2023 May 09, 2024	BUY	$39.12 - $49.85 $73,545 - $93,718	1,880 Added 17.24%	12,782 $587,000
Q2 2023 Apr 29, 2024	BUY	$23.58 - $44.68 $301,399 - $571,099	12,782 New	12,782 $539,000
Q2 2023 Aug 10, 2023	BUY	$23.58 - $44.68 $44,330 - $83,998	1,880 Added 17.24%	12,782 $539,000
Q1 2023 May 09, 2024	BUY	$25.42 - $33.52 $277,128 - $365,435	10,902 New	10,902 $284 Million
Q4 2022 May 10, 2024	SELL	$18.46 - $36.37 $37,972 - $74,813	-2,057 Reduced 15.87%	10,902 $324,000
Q4 2022 Mar 22, 2023	SELL	$18.46 - $36.37 $37,972 - $74,813	-2,057 Reduced 15.87%	10,902 $324,000
Q4 2022 Feb 15, 2023	SELL	$18.46 - $36.37 $37,972 - $74,813	-2,057 Reduced 15.87%	10,902 $324,000
Q3 2022 Jun 14, 2023	BUY	$13.55 - $19.92 $27,872 - $40,975	2,057 Added 18.87%	12,959 $251,000
Q2 2022 Jun 20, 2023	BUY	$7.4 - $15.07 $15,221 - $30,998	2,057 Added 18.87%	12,959 $175,000
Q1 2022 May 10, 2024	BUY	$11.65 - $19.57 $150,972 - $253,607	12,959 New	12,959 $180,000
Q1 2022 Jun 20, 2023	BUY	$11.65 - $19.57 $23,964 - $40,255	2,057 Added 18.87%	12,959 $180,000
Q1 2022 Mar 22, 2023	BUY	$11.65 - $19.57 $100,073 - $168,106	8,590 Added 196.61%	12,959 $180,000
Q1 2022 May 12, 2022	BUY	$11.65 - $19.57 $100,073 - $168,106	8,590 Added 196.61%	12,959 $180,000
Q4 2021 Jun 21, 2023	SELL	$18.01 - $30.1 $117,659 - $196,643	-6,533 Reduced 59.92%	4,369 $83,000
Q3 2021 May 17, 2024	SELL	$18.25 - $38.35 $176,094 - $370,039	-9,649 Reduced 68.83%	4,369 $98,000
Q3 2021 Jun 21, 2023	SELL	$18.25 - $38.35 $119,227 - $250,540	-6,533 Reduced 59.92%	4,369 $98,000
Q3 2021 Mar 22, 2023	SELL	$18.25 - $38.35 $119,227 - $250,540	-6,533 Reduced 59.92%	4,369 $98,000
Q3 2021 Nov 15, 2021	BUY	$18.25 - $38.35 $79,734 - $167,551	4,369 New	4,369 $99,000

Others Institutions Holding NUVL

# of Institutions

226

Shares Held

61M

Call Options Held

334K

Put Options Held

199K

View Full List

About Nuvalent, Inc.

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $3.29B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

More about NUVL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Account

Met Life Investment Management, LLC Nuvalent, Inc. Transaction History